Folic Acid Reduces Mucositis in Metastatic Renal Cell Carcinoma Patients: A Retrospective Study

Fristrup, Niels; Donskov, Frede

doi:10.1016/j.clgc.2019.03.023

Cited by 5 publications

(2 citation statements)

References 29 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Haematological and non-haematological toxicities were determined. Toxicity was graded in accordance with the Common Terminology Criteria for Adverse Events, version 4.0 12 . Patients were followed up until death or to early December 2018 if alive.…”

Section: Methodsmentioning

confidence: 99%

The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients

Wang

Gan

et al. 2020

Sci Rep

View full text Add to dashboard Cite

The aims of this study were to investigate the impact of the relative dose intensity (RDI) of chemotherapy on disease-free survival (DFS) and overall survival (OS), to identify the optimal RDI cutoff points with the docetaxel, epirubicin and cyclophosphamide (TEC) regimen for stage I-III breast cancer patients and to explore the adverse events in these patients. To achieve this, we performed a retrospective analysis of breast cancer patients treated at the First Affiliated Hospital of Chongqing Medical University in 2011. The results showed that among 293 patients with the TEC regimen, 85% and 80% were the cutoff points at which a high RDI was associated with better overall survival (HR = 2.04; 95% CI 1.13, 3.70; p = 0.02) and disease-free survival (HR = 1.97; 95% CI 1.14-3.42; p = 0.02), respectively. Among 169 HR(+) patients, 80% was the cutoff point for DFS (HR = 2.33; 95% CI 1.07-5.08; p = 0.03), and 85% was the cutoff point for OS (HR = 3.00; 95% CI 1.24-7.26; p = 0.02). Among 105 HR(−) patients, 80% was the cutoff point for OS (HR = 2.86; 95% CI 1.05-7.80; p = 0.04). Of 293 patients, neutropenia, nausea, and vomiting were found to be correlated with the level of RDI. In conclusion, a higher RDI of chemotherapy is associated with better survival but with a higher probability of causing adverse events. To optimize survival benefits, the RDI should be maintained ≥ 85% for HR(+) patients and ≥ 80% for HR(−) patients. The current standard of care for breast cancer includes breast surgery, local radiation therapy, systemic adjuvant and neoadjuvant chemotherapy, endocrine therapy and target therapy. Studies have shown the effect of chemotherapy on improving breast cancer survival 1-3. An increased benefit with anthracycline-containing regimens, which have been used increasingly over the past decade, has been recommended by The Early Breast Cancer Trialists' Collaborative Group 4. In addition, support for the adjuvant use of taxanes after an anthracycline-containing regimen was provided by Henderson et al. 's report (Intergroup Study 0148) 1,5. As an increasing number of trials have suggested an increased benefit with anthracycline and taxane-containing regimens, doctors have used taxanes combined with anthracycline as a classical regimen. The most famous clinical trial BCIRG005 suggested that patients receiving both doxorubicin and cyclophosphamide followed by docetaxel (AC-T) and docetaxel in combination with doxorubicin and cyclophosphamide (TAC) had a 79.0% 5-year disease-free survival rate. The 5-year overall survival rates were 89.0% and 88.0%, respectively 6. The 10-year overall survival rate was 79.9% in the ACT arm and 78.9% in the TAC arm. The ACT arm had a 66.5% 10-year disease-free survival rate, and the rate of the TAC arm was 66.3% 7. The survival benefits of the two regimens were similar, but the incidence of grade 3/4 adverse events in the blood system was lower in the ACT regimen than in the TAC regimen 6. However, the TAC regimen with G-CSF support provided a shorter duration of adjuvant therapy w...

show abstract

Section: Methodsmentioning

confidence: 99%

The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients

Wang

Gan

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…2,5,6 Mucositis and cutaneous side effects may affect the quality of life, resulting in dose reduction, discontinuation, or a change in treatment. 1,7 Cutaneous side effects associated with sunitinib are thought to be due to VEGF receptor inhibition occurring in proangiogenic pathways. 8 Sunitinib toxicity has demonstrated to be primarily associated with mitochondrial disorders.…”

Section: Introductionmentioning

confidence: 99%

Protective effect of adenosine triphosphate against sunitinib-related skin damage in rats

et al. 2020

View full text Add to dashboard Cite

Cutaneous side effects associated with sunitinib use are a major problem in patients receiving cancer treatment. The aim of this study was to investigate the protective effect of adenosine triphosphate (ATP) against possible skin damage resulting from sunitinib use in rats. Thirty Albino Winstar rats were divided into the following three groups: healthy controls (HCs, n = 10), sunitinib (SUN, n = 10), and sunitinib + ATP (SAT, n = 10). ATP was injected intraperitoneally at a dose of 2 mg/kg. One hour subsequent to the administration of ATP and 0.9% NaCl, the SAT and SUN groups were orally administered a dose of 25 mg/kg sunitinib to the stomach. Macroscopic evaluation of the skin indicated lower levels of skin damage in the SAT group than in the SUN group. As an indicator of oxidative stress, malondialdehyde (MDA), total oxidant status (TOS), and oxidative stress index (OSI) levels were significantly higher in the SUN group than in the HC group, while total glutathione (tGSH) and total antioxidant status (TAS) levels were significantly lower. However, MDA, TOS, and OSI levels were significantly lower in the SAT group than in the SUN group, while tGSH and TAS levels were significantly higher. Histopathological examination revealed keratin plugs with edema, vasopathology, and inflammatory cell infiltration in the SUN group. The SAT group showed less necrotic epithelium, keratin plugs, edema, and vasopathology than the SUN group. ATP can be effective in preventing skin damage caused by sunitinib use by reducing oxidative stress.

show abstract

Folic Acid: A New Weapon for Mucositis?

Alkan

Türkkan

Tanrıverdi

2019

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

Folic Acid Reduces Mucositis in Metastatic Renal Cell Carcinoma Patients: A Retrospective Study

Cited by 5 publications

References 29 publications

The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients

The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients

Protective effect of adenosine triphosphate against sunitinib-related skin damage in rats

Folic Acid: A New Weapon for Mucositis?

Contact Info

Product

Resources

About